Tests hint at trouble with pairing cystic fibrosis drugs | Science News

ADVERTISEMENT

SUPPORT SCIENCE NEWS

Science News is a nonprofit.

Help us keep you informed.



Science Ticker

A roundup of research
and breaking news

Science News Staff
Science Ticker

Tests hint at trouble with pairing cystic fibrosis drugs

Sponsor Message

Combining two types of cystic fibrosis drugs may cancel out the benefits of one of the medications. In cultures of human cells, ivacaftor, the cystic fibrosis drug sold under the trade name Kalydeco, may destabilize proteins. These proteins are disease-related and are targeted and corrected by drugs such as lumacaftor, two teams report July 23 in Science Translational Medicine. The findings contrast with positive results recently released from one of the two large clinical trials that combine ivacaftor and lumacaftor.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content